Global  

J&J, AstraZeneca resuming trials of vaccines

Video Credit: Reuters Studio - Duration: 01:08s - Published
J&J, AstraZeneca resuming trials of vaccines

J&J, AstraZeneca resuming trials of vaccines

AstraZeneca has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial early next week, the companies said on Friday.

Fred Katayama reports.


You Might Like


💡 One News Page Knowledge: Other News Mentions

Johnson & Johnson Johnson & Johnson U.S. multinational medical manufacturer

Johnson & Johnson vows to add 50% more Black managers in five years. Here's how.

Johnson & Johnson pledges $100 million to boost diversity within its management ranks and provide college scholarships for Black students.

USATODAY.com
Missouri Supreme Court blocks J&J’s damages appeal [Video]

Missouri Supreme Court blocks J&J’s damages appeal

Missouri's highest court on Tuesday refused to consider Johnson & Johnson's appeal of a $2.12 billion damages award to women who blamed their ovarian cancer on asbestos in its baby powder and other talc products. Bryan Wood reports.

Credit: Reuters Studio    Duration: 01:08Published
Global COVID-19 cases rise by a one-day record [Video]

Global COVID-19 cases rise by a one-day record

Global coronavirus cases rose by more than 400,000 for the first time late on Friday, a record one-day increase as much of Europe enacts new restrictions to curb the outbreak. Freddie Joyner has more.

Credit: Reuters - Politics    Duration: 01:18Published
Johnson & Johnson Halts COVID-19 Vaccine Trial Due to Unexplained Illness [Video]

Johnson & Johnson Halts COVID-19 Vaccine Trial Due to Unexplained Illness

Johnson & Johnson has paused the advanced clinical trial of its experimental COVID-19 vaccine after one of their 60,000 participants became ill.

Credit: Cover Video STUDIO    Duration: 01:19Published

AstraZeneca British-Swedish pharmaceutical company

Questions over AstraZeneca's COVID-19 vaccine data [Video]

Questions over AstraZeneca's COVID-19 vaccine data

British drugmaker AstraZeneca is working with regulators to investigate a lower dosage of its vaccine that performed better than a full dosage, a spokesman for the company said on Thursday, after its chief executive was quoted as saying an additional global trial was likely. This report produced by Jillian Kitchener.

Credit: Reuters - Politics    Duration: 01:29Published
AstraZeneca Admits COVID Breakthrough Came From Mistake [Video]

AstraZeneca Admits COVID Breakthrough Came From Mistake

AstraZeneca and the University of Oxford are facing criticism over their COVID-19 vaccine trial results. According to Business Insider the criticism comes after AstraZeneca admitted to a mistake in the vaccine dosage. During the vaccine trial, some patients got two full doses of the vaccine. Others had a half-dose in their first shot, followed by a full dose. On Wednesday, an AstraZeneca executive described the "mistake" as "serendipity.

Credit: Wochit News    Duration: 00:36Published
Dosing Mix-up Raises Questions About New COVID Vaccine [Video]

Dosing Mix-up Raises Questions About New COVID Vaccine

A manufacturing error is raising concerns about a promising COVID-19 vaccine being developed. The vaccine was developed by pharmaceutical company AstraZeneca and the University of Oxford. Less than a week after we learned about it, the developers have admitted to a manufacturing error. The error resulted from two different doses during the recently concluded phase III trial. AstraZeneca and the University of Oxford described the vaccine as being 70% effective.

Credit: Wochit News    Duration: 00:39Published

PM to visit vaccine centres in 3 cities

While in Hyderabad, the PM will visit vaccine maker Bharat Biotech’s facilities, where work on the development of India’s first indigenous Covid-19 vaccine,..
IndiaTimes

Coronavirus disease 2019 Coronavirus disease 2019 Disease caused by severe acute respiratory syndrome coronavirus 2

BREAKING: Fire breaks out at ICU of COVID hospital Gujarat's Rajkot, 3 dead

There were seven COVID patients at the ICU unit of the Uday Shivanand Hospital at the time of the incident.
DNA
Moderna's COVID-19 Vaccine Designed Designed In 2 Days [Video]

Moderna's COVID-19 Vaccine Designed Designed In 2 Days

Moderna's coronavirus vaccine candidate is 94.5% effective at protecting people against COVID-19. The candidate took under a year to develop and test, which is years faster than previous vaccines. The company designed its vaccine candidate in just two days, says Business Insider. In contrast, traditional vaccines can take years to design. Vaccines will hopefully be rolled out by Spring of 2021.

Credit: Wochit News    Duration: 00:33Published

Daily infections hold steady, active cases are on rise

. There were little signs yet of the feared second wave of the pandemic as nationwide cases totalled up to 43,279 on Thursday, a slight drop from Wednesday's..
IndiaTimes

Covid-positive Rajasthan health minister goes on hospital jaywalk

Rajasthan health minister Raghu Sharma has given the phrase “going viral” a new definition by choosing to go about inspecting and interacting with patients..
IndiaTimes

Fred Katayama

Dow, S&P pull back from record highs [Video]

Dow, S&P pull back from record highs

The S&P 500 and Dow closed lower Wednesday as mounting U.S. layoffs in the wake of new lockdowns to contain surging COVID-19 infections dampened investor risk appetite. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:38Published
Slowing labor market recovery weighs on stocks [Video]

Slowing labor market recovery weighs on stocks

The S&P 500 and the Dow retreated Wednesday as a surprise rise in weekly jobless claims added to signs the recovery of the labor market was stalling amid a surge in COVID-19 infections. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:41Published
G20 to pledge to pay for fair access to vaccines [Video]

G20 to pledge to pay for fair access to vaccines

Leaders of the world's 20 biggest economies on Sunday will pledge to pay for a fair distribution of COVID-19 vaccines, drugs and tests around the world so that poorer countries are not left out, and to extend debt relief to them, a draft G20 communique showed. Fred Katayama reports.

Credit: Reuters - Politics    Duration: 01:11Published
Wisconsin governor renews mask mandate [Video]

Wisconsin governor renews mask mandate

Wisconsin's governor on Friday extended a statewide mask mandate despite a legal challenge from conservatives, renewing an emergency health order requiring face coverings in public spaces to curb an alarming surge in COVID-19 infections. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:05Published

Related news from verified sources

AstraZeneca's coronavirus vaccine trial can continue in the US after being halted due to a participant having a 'serious adverse reaction'

AstraZeneca and the University of Oxford to resume late-stage trials for a COVID-19 vaccine in the...
Business Insider - Published

Covid 19 coronavirus AstraZeneca vaccine: Volunteer dies during human trials

Covid 19 coronavirus AstraZeneca vaccine: Volunteer dies during human trials A volunteer taking part in the trial for AstraZeneca's Covid-19 vaccine, which Australians could be...
New Zealand Herald - Published

COVID-19 vaccine trial participant DIES... AstraZeneca downplays the death and continues the medical experiments on the remaining humans

(Natural News) A person who volunteered for the medical experimentation on humans with the COVID-19...
NaturalNews.com - Published


Related videos from verified sources

How the AstraZeneca-Oxford COVID Vaccine Works [Video]

How the AstraZeneca-Oxford COVID Vaccine Works

LONDON — The University of Oxford and AstraZeneca's coronavirus vaccine was 90 percent effective in preventing COVID-19 In studies of more than 22,000 people in the UK and Brazil, AstraZeneca said in..

Credit: TomoNews US     Duration: 01:58Published
AstraZeneca, 3rd Major COVID-19 Vaccine, Shown to Be Effective and Cheaper [Video]

AstraZeneca, 3rd Major COVID-19 Vaccine, Shown to Be Effective and Cheaper

On Monday, the drugmaker announced the "exciting results" based on an analysis of trials in the UK and Brazil.

Credit: Cover Video STUDIO     Duration: 01:09Published
AstraZeneca COVID-19 vaccine can be 90% effective, results show [Video]

AstraZeneca COVID-19 vaccine can be 90% effective, results show

UK group is the latest drugmaker to unveil positive interim data in a scientific race to curb a global pandemic.

Credit: Al Jazeera STUDIO     Duration: 02:17Published